



The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors

Washington, DC – October 21, 2021

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2022 Officers, Executive Committee, and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM's strategic priorities and focus areas for the coming year.

"ARM welcomes the diverse expertise and experience of our 2022 Board of Directors," said ARM Chief Executive Officer Janet Lambert. *"Our sector is poised to shape healthcare for years to come and our Board will be instrumental in advancing the delivery of transformative therapies for patients globally, while helping to eradicate barriers and legacy policy that could slow access."*

ARM 2022 Officers:

Emile Nuwaysir, Ph.D. – *Chief Executive Officer, Ensoma (Chairman)*

Usman 'Oz' Azam, M.D. – *President and Chief Executive Officer, Tmunity Therapeutics (Vice Chairman)*

Amy Butler, Ph.D. – *President, Biosciences, Thermo Fisher Scientific (Secretary)*

Devyn Smith, Ph.D. – *Chief Executive Officer, Arbor Biotechnologies (Treasurer)*

ARM 2022 Executive Committee:

Usman 'Oz' Azam, M.D. – *President and Chief Executive Officer, Tmunity Therapeutics*

Amy Butler, Ph.D. – *President, Biosciences, Thermo Fisher Scientific*


Miguel Forte, M.D., Ph.D. – *Chief Executive Officer, Bone Therapeutics*

Claudia Mitchell, MBA, Ph.D. – *Senior Vice President, Product and Portfolio Strategy, Astellas Pharma*

Emile Nuwaysir, Ph.D. – *Chief Executive Officer, Ensoma*

Bob Smith, MBA – *Senior Vice President, Global Gene Therapy Business, Pfizer*

Devyn Smith, Ph.D. – *Chief Executive Officer, Arbor Biotechnologies*



Arthur Tzianabos, Ph.D. – *President and Chief Executive Officer, Homology Medicines*

Christopher Vann – *Senior Vice President and Chief Operating Officer, Autolus Therapeutics*

ARM 2022 Board of Directors

* *New to the Board for 2022*

Usman 'Oz' Azam, M.D. – *President and Chief Executive Officer, Tmunity Therapeutics*

Mark Battaglini – *Senior Vice President, Global External Affairs & US Government Payer, bluebird bio*

Amy Butler, Ph.D. – *President, Biosciences, Thermo Fisher Scientific*

Bradley Campbell, MBA – *President and Chief Operating Officer, Amicus Therapeutics*

Miguel Forte, M.D., Ph.D. – *Chief Executive Officer, Bone Therapeutics*

Bobby Gaspar, M.D., Ph.D. – *Chief Executive Officer, Orchard Therapeutics*

Jerry Keybl, Ph.D. – *Senior Director, Cell & Gene Therapy, MilliporeSigma*

Brett Kopelan – *Executive Director, Debra of America*

Dave Lennon, Ph.D. – *Former President, Novartis Gene Therapies*

Bruce Levine, Ph.D. – *Founding Director, Clinical Cell and Vaccine Production Facility, Abramson Cancer Center, University of Pennsylvania*

* Timothy Lu, M.D., Ph.D. – *Chief Executive Officer, Senti Biosciences*

John Maslowski, M.S. – *Chief Commercial Officer, Forge Biologics*

* Chris Mason, M.D., Ph.D. – *Chief Scientific Officer, AVROBIO*

* Debra Miller – *Chief Executive Officer & Founder, CureDuchenne*

Claudia Mitchell, MBA, Ph.D. – *Senior Vice President, Product and Portfolio Strategy, Astellas Pharma*

* Alison Moore, Ph.D. – *Chief Technology Officer, Allogene Therapeutics*

Adora Ndu, PharmD, J.D. – *Group Vice President, Worldwide Research & Development Strategy, Scientific Collaborations and Policy, BioMarin*

Susan Nichols – *President & Chief Executive Officer, Propel BioSciences*

Emile Nuwaysir, Ph.D. – *Chief Executive Officer, Ensoma*

Karah Parschauer, J.D. – *Executive Vice President, General Counsel and Corporate Secretary, Ultragenyx*

Louise Rodino-Klapac, Ph.D. – *Executive Vice President, Chief Scientific Officer, Sarepta Therapeutics*

Jeff Ross, Ph.D. – *Chief Executive Officer, Miromatrix Medical*

* Laura Sepp-Lorenzino, Ph.D. – *Executive Vice President, Chief Scientific Officer, Intellia Therapeutics*

R.A. Session, MBA – *President, Founder & Chief Executive Officer, Taysha Therapeutics*

Curran Simpson, M.S. – *Senior Vice President, Product Development and CTO, REGENXBIO*

Sanjaya Singh, Ph.D. – *Vice President & Global Head, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development*

Bob Smith, MBA – *Senior Vice President, Global Gene Therapy, Pfizer*

Devyn Smith, Ph.D. – *Chief Executive Officer, Arbor Biotechnologies*

Joseph Tarnowski, Ph.D. – *Senior Vice President of Cell and Gene Therapy Platforms, Medicinal Science & Technology, R&D*

Arthur Tzianabos, Ph.D. – *President and Chief Executive Officer, Homology Medicines*

Christopher Vann – *Senior Vice President and Chief Operating Officer, Autolus Therapeutics*

Kristin Yarema, Ph.D. – *Chief Commercial Officer, Atara Biotherapeutics*